Fig. 10From: Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of gliomaValidation of the expression levels of 6 DRLs in 12 non-tumor brain tissues and 12 glioma tissues. (A-F). The expression level of 6 DRLs (LINC00641, AL139232.1, AL390755.1, LEF1-AS1, LYRM4-AS1, and AL691432.4) in 12 non-tumor brain tissues and 12 glioma tissues. **p < 0.01, ***p < 0.001Back to article page